Business
Final Results for the year ended December 31, 2019
Final Results for the year ended December 31, 2019.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n RNS Number : 8965G\n Faron Pharmaceuticals Oy\n 20 March 2020\n \n \n \n \n Faron Pharmaceuticals Oy\n \n \n (\"Faron\" or the \"Company\")\n \n \n \n \n \n Financial statement release January 1 to December 31, 2019\n \n \n \n \n \n \n Financial statement release, \n \n \n Turku, 20 March 2019 at 9.00 AM (EET)\n \n \n \n Inside information\n \n \n \n \n \n \n TURKU, FINLAND - \n \n Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, \n today reports its financial statements for the year ended 31 December 2019 and H2 2019.\n \n \n \n \n \n HIGHLIGHTS\n \n \n \n \n \n Operational (including post period):\n \n \n \n \n \n \n Clevegen®\n \n - Regulator of major inhibitory immune checkpoints and wholly-owned novel cancer immunotherapy in development\n \n \n • Part I of the open label phase I/II MATINS trial, initiated across multiple sites through Europe and primarily intended to investigate safety and tolerability, was completed with dose escalation reaching its planned maximum level of 10mg/kg. Clevegen demonstrated good tolerability at all dosing levels (0.1 to 10 mg/kg) without dose limiting toxicity.\n \n \n • Clevegen promoted immune activation in all dosed patients, measured following treatment with Clevegen and observed as increased circulating CD8+ T cells and CD8+/CD4+ ratio, decreased regulatory T-cells (T-regs) or a substantial increase in mobile natural killer (NK) cells in the blood.\n \n \n • Partial responses were observed in two patients. The first, a colorectal cancer (CRC) patient, showed a continuation of lung and lymph node metastasis shrinkage and their tumour load biochemical marker, carcinoembryonic antigen (CEA), also normalised. The second, a heavily pre-treated melanoma patient, showed a reduction in the size of the target lesion tumour (a lung metastasis) by 44 percent and other non-target lesions stabilized. Their biochemical tumour load marker also declined and clearance of pleura fluid was observed.\n \n \n • Data showing Clevegen's potential early efficacy and good tolerability were presented at the European Society of Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain. At the Society's subsequent Immuno-Oncology Congress 2019 in Geneva, Switzerland, more detailed ce...